Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

Clinical trial NCT06799013 · RECRUITING

Trial details

NCT number: NCT06799013
Sponsor: HDT Bio
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Vaccine Crimean-Congo Hemorrhagic Fever

Start date: 2025-07-10
Primary completion: 2026-12-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.